Ali Albeer

Project Title

Investigating Prognostic Factors for Disease Progression in Treatment-Free Remission Patients with Chronic Myeloid Leukaemia after Tyrosine Kinase Inhibitor Discontinuation

Research Interest

The objective of this project is to assess previously established factors and identify new potential predictors that may influence the ability to maintain treatment-free remission (TFR) in patients who discontinue tyrosine kinase inhibitor (TKI) therapy. Through the analysis of various clinical, molecular, and patient-specific variables, this research seeks to provide a comprehensive understanding of the key determinants of successful TFR. Furthermore, the study aims to compare its findings with existing literature to assess consistency with prior research and to offer new contributions to the evolving field chronic myeloid leukemia (CML) management. In addition, this study focuses specifically on TFR in patients who have discontinued nilotinib, a second-generation TKI, as opposed to imatinib, a first-generation TKI that has been the primary focus of larger studies and prior research.

Supervisor(s)

Prof. Markus Pfirrmann

Curriculum Vitae

EDUCATION

Since 10/2025 - Ph.D. Candidate in Medical Research, Epidemiology & Public Health, LMU Munich, Germany

MSc: 2017 – 2019, Ludwig-Maximilians-University (LMU) – Munich - Germany, MSc Epi
BSc: 2005 – 2011, University of Baghdad/College of Medicine – Baghdad - Iraq, MBChB.

WORK EXPERIENCE

2012-2013: Medical Doctor in Ministry of Health (MoH) of Iraq.
2014-2016: Medical Activity Manager with Doctors Without Borders (MSF) in Iraq and South Sudan.
2019-now: Epidemiologist/Researcher in Inistitute of Medical Information Processing, Biometry and Epidemiology (IBE) in Munich, Germany

Publications

1- Nissen M, Tröbs RB, Albeer A. Pediatric appendicitis may be co-associated with meteorologic factors: A case-crossover study. Pediatr Neonatol. 2025 Jul;66(4):323-328. doi: 10.1016/j.pedneo.2024.04.016. Epub 2024 Sep 25. PMID: 39394032.

2- Machova Polakova K, Albeer A, Polivkova V, Krutska M, Vlcanova K, Curik N, Fabarius A, Klamova H, Spiess B, Waller CF, Brümmendorf TH, Dengler J, Kunzmann V, Burchert A, Belohlavkova P, Mustjoki S, Faber E, Mayer J, Zackova D, Panayiotidis P, Richter J, Hjorth-Hansen H, Kamińska M, Płonka M, Szczepanek E, Szarejko M, Bober G, Hus I, Grzybowska-Izydorczyk O, Wasilewska E, Paczkowska E, Niesiobędzka-Krężel J, Giannopoulos K, Mahon FX, Sacha T, Saußele S, Pfirrmann M. The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia. 2024 Feb;38(2):318-325. doi: 10.1038/s41375-023-02109-2. Epub 2023 Dec 21. PMID: 38129513; PMCID: PMC10844071.

3- Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, Pfirrmann M; International BCR-ABL Study Group. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia. 2019 May;33(5):1173-1183. doi: 10.1038/s41375-018-0341-4. Epub 2019 Jan 23. PMID: 30675008.